key: cord-0735524-eu79bzvq
authors: Malinis, Maricar; Cohen, Elizabeth; Azar, Marwan M.
title: Response to “SARS‐CoV‐2 vaccine effectiveness trumps immunogenicity in solid organ transplant recipients”
date: 2021-08-12
journal: Am J Transplant
DOI: 10.1111/ajt.16770
sha: 99c4e2339700137d416212a3b2f5fabb237c4825
doc_id: 735524
cord_uid: eu79bzvq

We recently reported a SARS-CoV-2 infection breakthrough rate of 0.65% (3/459) among fully vaccinated adult solid organ transplant recipients (SOTr) at our institution as of May 18,2021(1). The majority of fully vaccinated SOTr consisted of kidney recipients (319/459, 70%), with a minority of liver (85/459, 19%), heart (41/459, 9%), and multi-visceral transplants (11/459, 2%). Sixty-five percent was on a mycophenolate-containing regimen (Table 1) and mycophenolate with tacrolimus and prednisone was the most common regimen (33%). In response to our letter, Mossad(2) pointed out that our findings may not be generalizable to other centers whose SOTr population may be more highly immunosuppressed and/or more vulnerable to respiratory infections such as lung and multi-visceral SOTr. Furthermore, Mossad noted that SOTr with prior undocumented SARS-CoV-2 infection and thus with some level of protection from reinfection might have been included.

To the Editor:

We recently reported a SARS-CoV-2 infection breakthrough rate of 0.65% (3/459) among fully vaccinated adult solid organ transplant recipients (SOTr) at our institution as of May 18, 2021. 1 The majority of fully vaccinated SOTr consisted of kidney recipients (319/459, 70%), with a minority of liver (85/459, 19%), heart (41/459, 9%), and multi-visceral transplants (11/459, 2%). Sixty-five percent was on a mycophenolate-containing regimen ( Table 1 ) and mycophenolate with tacrolimus and prednisone was the most common regimen (33%). In response to our letter, Mossad 2 pointed out that our findings may not be generalizable to other centers whose SOTr population may be more highly immunosuppressed and/or more Our study focused on the clinical effectiveness of the SARS-CoV-2 vaccine. Side effects were not reported as it was not the intention of the study. Also, chart review may not be able to describe side effects, particularly mild ones, accurately. In a prior study by

Effectiveness of SARS-CoV-2 vaccination in fully-vaccinated solid organ transplant recipients

SARS-CoV-2 vaccine effectiveness trumps immunogenicity in solid organ transplant recipients

Antibody responses to SARS-CoV-2 at 8 weeks postinfection in asymptomatic patients

Lack of antibodies to SARS-CoV-2 in a large cohort of previously infected persons

Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients

Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients